No connection

Search Results

ABBV vs IQV

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
IQV
IQVIA Holdings Inc.
BULLISH
Price
$158.98
Market Cap
$26.69B
Sector
Healthcare
AI Confidence
82%

Valuation

P/E Ratio
ABBV
163.63
IQV
20.25
Forward P/E
ABBV
15.42
IQV
11.29
P/B Ratio
ABBV
-146.66
IQV
4.15
P/S Ratio
ABBV
6.5
IQV
1.64
EV/EBITDA
ABBV
15.27
IQV
14.05

Profitability

Gross Margin
ABBV
71.46%
IQV
33.29%
Operating Margin
ABBV
35.5%
IQV
15.17%
Profit Margin
ABBV
4.0%
IQV
8.34%
ROE
ABBV
137.96%
IQV
21.44%
ROA
ABBV
9.59%
IQV
5.05%

Growth

Revenue Growth
ABBV
9.1%
IQV
10.3%
Earnings Growth
ABBV
-88.7%
IQV
23.6%

Financial Health

Debt/Equity
ABBV
--
IQV
2.46
Current Ratio
ABBV
0.72
IQV
0.75
Quick Ratio
ABBV
0.47
IQV
0.67

Dividends

Dividend Yield
ABBV
3.05%
IQV
--
Payout Ratio
ABBV
490.15%
IQV
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
IQV BULLISH

IQVIA exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a highly attractive PEG ratio of 0.68, suggesting significant undervaluation relative to its growth. While the stock is currently trading at a premium to its Graham Number ($82.24), it sits well below its intrinsic value ($231.28) and analyst targets ($231.60). However, the bullish fundamental outlook is contrasted by a severe technical downtrend and liquidity concerns, evidenced by a current ratio of 0.75 and high leverage. Overall, the company's robust ROE and consistent earnings growth make it a strong value play despite short-term price volatility.

Strengths
Strong Piotroski F-Score (7/9) indicating healthy financial trends
Highly attractive PEG ratio (0.68) suggesting growth is underpriced
Robust Return on Equity (ROE) of 21.44%
Risks
Poor short-term liquidity with a current ratio of 0.75
High leverage with a Debt/Equity ratio of 2.46
Severe bearish technical trend (0/100) and recent 6-month price decline of 27.1%

Compare Another Pair

ABBV vs IQV: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and IQVIA Holdings Inc. (IQV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile